
ANMI Transaction – Investor Conference Call

Audio recording available

Melbourne (Australia) – 3rd December 2018. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), is pleased to provide investors an audio link to the Investor Conference Call hosted by the Company and led by Managing Director and Group CEO, Dr Christian Behrenbruch, on Friday 30 November 2018.

Investors can access the audio recording here: <http://www.telixpharma.com/wp-content/uploads/2018/12/Telix-Pharma-Acquisition-of-ANMI-Investor-Conference-Call-301118-1.mp3>

Investors can access the market briefing presentation here:
<https://www.asx.com.au/asxpdf/20181126/pdf/440mc4t3scgf39.pdf>

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited (“Telix”) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (Japan) and Indianapolis (USA). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
Group CEO
Email: chris@telixpharma.com

Telix Investor Relations (Australia)

Arthur Chan
WE Buchan
Tel: +61 (2) 9237 2805
Email: telix@we-buchan.com

Telix Investor Relations (US)

Lisa Wilson
In-Site Communications
Tel: +1 212 452 2793
Email: lwilson@insitecony.com